Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.
暂无分享,去创建一个
[1] H. Holthöfer,et al. Hypercholesterolemia is a prerequisite for puromycin inducible damage in mouse kidney. , 2003, Kidney international.
[2] M. Cooper,et al. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] C. Mogensen. The kidney in diabetes: how to control renal and related cardiovascular complications. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] M. Cooper,et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.
[5] M. Cooper,et al. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. , 2000, Kidney international.
[6] H. Koomans,et al. ACE inhibition delays development of terminal renal failure in the presence of severe albuminuria. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] G. Remuzzi,et al. The role of protein traffic in the progression of renal diseases. , 2000, Annual review of medicine.
[8] B. Fabris,et al. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. , 1999, Journal of hypertension.
[9] R. Bain,et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] N. Perico,et al. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] C. Johnston,et al. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. , 1999, The American journal of pathology.
[12] M. Cooper,et al. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. , 1999, Kidney international.
[13] M. Mulvany. Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. , 1998, Metabolism: clinical and experimental.
[14] F. Martin,et al. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. , 1998, Metabolism: clinical and experimental.
[15] R. Ferrari. Effect of ACE inhibition on myocardial ischaemia. , 1998, European heart journal.
[16] M. Cooper,et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.
[17] J. Mullins,et al. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27 , 1998, Journal of hypertension.
[18] S. Anderson. Role of local and systemic angiotensin in diabetic renal disease. , 1997, Kidney international. Supplement.
[19] C. Tsalamandris,et al. Why is proteinuria such an important risk factor for progression in clinical trials? , 1997, Kidney international. Supplement.
[20] O. E. Michaelis,et al. Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. , 1997, Hypertension.
[21] M. Cooper,et al. Role of Angiotensin II and Bradykinin in Experimental Diabetic Nephropathy: Functional and Structural Studies , 1997, Diabetes.
[22] W. Fierlbeck,et al. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. , 1997, Kidney international.
[23] M. Myers. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. , 1996, The Canadian journal of cardiology.
[24] J. Campbell,et al. Short-term and long-term cardiovascular actions of different doses of perindopril in the rabbit. , 1996, Pharmacological research.
[25] K. Duggan,et al. DIFFERENTIAL EFFICACY OF PERINDOPRIL AND ENALAPRIL IN EXPERIMENTAL DIABETIC NEPHROPATHY , 1996, Clinical and experimental pharmacology & physiology.
[26] G. Remuzzi,et al. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] D. Sutherland,et al. Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression. , 1995, Kidney international.
[28] T. Unger,et al. Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. , 1995, The American journal of cardiology.
[29] D. Ganten,et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin–angiotensin-system gene expression and cardiovascular functions , 1995, Journal of hypertension.
[30] D. Heudes,et al. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[31] M. Cooper,et al. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. , 1995, American journal of hypertension.
[32] I. Antony,et al. Clinical review of perindopril in the treatment of hypertension. , 1994, The Canadian journal of cardiology.
[33] G. Bakris,et al. Microalbuminuria and progressive renal disease. , 1994, Journal of human hypertension.
[34] N. Perico,et al. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. , 1994, Journal of the American Society of Nephrology : JASN.
[35] S. Anderson,et al. Glomerular adaptations with normal aging and with long-term converting enzyme inhibition in rats. , 1994, The American journal of physiology.
[36] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[37] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[38] J. Ingelfinger,et al. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. , 1993, The American journal of physiology.
[39] G. Jerums,et al. The Effects of Perindopril and Triple Therapy in a Normotensive Model of Diabetic Nephropathy , 1993, Diabetes.
[40] G. Jerums,et al. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. , 1992, Kidney international.
[41] A. Fogo,et al. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. , 1991, Kidney international.
[42] G. Viberti,et al. Risk factors for renal and cardiovascular disease in diabetic patients. , 1991, The Cardiology.
[43] J. Reid,et al. Perindopril. A review of its pharmacokinetics and clinical pharmacology. , 1990, Drugs.
[44] B. Brenner,et al. Short and long term effects of antihypertensive therapy in the diabetic rat. , 1989, Kidney international.
[45] G. Jerums,et al. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. , 1988, American journal of hypertension.
[46] B. Brenner,et al. Reversing glomerular hypertension stabilizes established glomerular injury in renal ablation. , 1986, Journal of Hypertension - Supplement.
[47] R. Buñag. Validation in awake rats of a tail-cuff method for measuring systolic pressure. , 1973, Journal of applied physiology.